Robert L. De Jager, M.D., F.A.C.P. Joins Conforma Therapeutics as Vice President, Clinical Research & Development and Chief Medical Officer.SAN DIEGO -- Conforma Therapeutics Corporation today announced the appointment of Robert L. De Jager, M.D., F.A.C.P to the newly created position of vice president, clinical research and development and chief medical officer. In this position, Dr. De Jager will oversee the clinical evaluation clinical evaluation Medtalk An evaluation of whether a Pt has symptoms of a disease, is responding to treatment, or is having adverse reactions to therapy of CNF CNF Configuration (File Name Extension) CNF Conference CNF Conjunctive Normal Form CNF Could Not Find CNF Chin National Front (Burma) CNF Canadian Nature Federation CNF Cornell NanoScale Facility 1010, Conforma's geldanamycin-derived HSP (Hosting Service Provider) An organization that specializes in hosting Web sites. There are various levels of offerings from sharing a Web server with several other companies to having a dedicated Web server or to providing co-location services. See co-location. 90 inhibitor currently in Phase I clinical trials in cancer, and CNF2024, a synthetic oral HSP90 inhibitor recently selected as a clinical candidate and expected to enter clinical trials in cancer in 2005. "Dr. De Jager has outstanding clinical trials experience and proven leadership skills," said Lawrence C. Fritz, Ph.D., president and chief executive officer of Conforma. "The addition of Robert to Conforma's management team underscores our emergence as a development-stage pharmaceutical company." Dr. De Jager has over 30 years of experience in the development of anti-cancer chemotherapy, biologics, and gene therapy. He has contributed to the treatment of breast, gastric, lung, and bladder cancers. He joins Conforma from Daiichi Pharmaceutical Corporation, the U.S.-based subsidiary of Daiichi Pharmaceutical Co., Ltd., Tokyo, Japan. From 1997 until joining Conforma, Dr. De Jager held increasingly senior leadership positions at Daiichi, most recently as vice president, R&D, oncology and internal medicine. During this period he designed and directed numerous cancer clinical trials, covering the range of Phase I to Phase III testing. Prior to Daiichi, Dr. De Jager worked in cancer clinical development at both large and small pharmaceutical companies, including RGene Therapeutics, (The Woodlands, TX); the Akzo-Nobel subsidiary PerImmune, Inc., (Rockville, MD); and Sanofi Research, (Paris, France). He has had extensive interactions with the U.S. Food and Drug Administration and with European regulatory agencies, and his efforts have led to the successful development and registration of several cancer drugs. In addition to his work in the pharmaceutical and biotechnology industries, Dr. De Jager has also led a distinguished academic career. He has held staff positions at the Memorial Sloan Kettering Cancer Center, (New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of , NY); the Institut Jules Bordet Institut Jules Bordet is a hospital and research institute that specializes in oncology. It is located in Brussels, Belgium. Namesake The institute is named after Jules Bordet (1870 – 1961), a Belgian immunologist and microbiologist who won the Nobel Prize in , (Brussels, Belgium); the Institut de Cancerologie et d'Immunogenetique, (Villejuif, France); and the University of Medicine and Dentistry of New Jersey The University of Medicine and Dentistry of New Jersey is the state-run health sciences institution of New Jersey and comprises eight distinct academic units: the New Jersey Medical School, the New Jersey Dental School, the Graduate School of Biomedical Sciences, the School of , (Newark, NJ), where he was professor of medicine and director of the Medical Oncology division. Dr. De Jager has also been an adjunct associate professor of medicine at the University of Texas M.D. Anderson Cancer Center, a member of the E.O.R.T.C. Early Clinical Trials group, a founding member of the E.O.R.T.C. Clinical Pharmacology group and an E.C.O.G. investigator. Dr. De Jager holds an M.D. degree from the Free University of Brussels The Free University of Brussels may refer to one of two Belgian universities, both located in Brussels, Belgium:
adj the status of a dental specialist such as an orthodontist who has become a board diplomate by successfully completing the certification program of the recognized certification board in that area of practice. in Internal Medicine and Medical Oncology. About Conforma Therapeutics Conforma Therapeutics, a San Diego-based biopharmaceutical company, is focused on the design and development of novel drugs for the treatment of cancer. Conforma is developing drugs that target the cellular HSP90 family of molecular "chaperones" that control protein shape or conformation, including that of key signaling molecules involved in the growth and survival of tumor cells. HSP90-directed drugs selectively induce the degradation of these cancer-promoting proteins, leading to tumor cell death. In addition to cancer, Conforma's technology also promises to have applications in other areas of medicine, including inflammation, virology virology, study of viruses and their role in disease. Many viruses, such as animal RNA viruses and viruses that infect bacteria, or bacteriophages, have become useful laboratory tools in genetic studies and in work on the cellular metabolic control of gene expression , and central nervous system disorders Nervous system disorders A satisfactory classification of diseases of the nervous system should include not only the type of reaction (congenital malformation, infection, trauma, neoplasm, vascular diseases, and degenerative, metabolic, toxic, or deficiency . Conforma is conducting Phase I clinical trials with its lead product, CNF1010, for the treatment of cancer, and is also developing a pipeline of additional differentiated, molecularly targeted oncology products. Further information regarding Conforma is available at www.conformacorp.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion